SLC5A2 and metabolic dysfunction-associated steatotic liver disease: In a recentmeta-analysis, SGLT2 inhibitors trended towards reduced steatosis (standard mean difference (SMD) –4.64,p = 0.06), nevertheless, these results were non-significant [62].Another meta-analysis has shown that alanine transaminase (WMD –5.36 [95% CI:–8.86 to –1.85], p = 0.003) and aspartate transaminase (weighted mean difference –2.56[95% CI: –3.83 to –1.29], p < 0.0001) levels are significantlyreduced in patients with NAFLD and T2DM with the use of SGLT2 inhibitors versusother antidiabetic treatments, including pioglitazone [63].